Abstracteinreichung

Die Abstracteinreichung ist geschlossen


Guidelines für die Abstracteinreichung (in Englisch)

All abstracts have to be submitted in one language only (German, French, or English).

Each abstract requires:

  • Title (please do not use capitals only, e.g. use "ERG in Glaucoma" instead of "ERG IN GLAUCOMA". Use American spelling and verify with the appropriate spell-check.)
  • A maximum of 2500 characters (including spaces), including the sections Purpose, Methods, Results, and Conclusion.
  • Mentioning of all authors
  • Mentioning of all affiliations (corresponding company/institution, department, location, and country)

Disclosure of Financial Interests and Grants (at the end of the abstract):

  • Support from a for-profit company or competing company
  • Personal investment in a company or competing company (other than through a mutual or retirement fund)
  • Employment by a company or competing company with business interest in the topic
  • Being a consultant of a company or competing company with business interest in the topic
  • Inventor/Developer of the topic or a competing topic
  • Travel Reimbursement, gifts or honoraria of over $3000 in the last twelve months by a company or competing company involved
  • None: No commercial relationship

By submitting the abstract, the first author certifies that

  • the material submitted has not been published previously,
  • investigations on human subjects have been reviewed by the local ethical committee and are in accordance with the tenets of the Declaration of Helsiniki,
  • animal studies comply with the "ARVO Statement for the Use of Animals in Ophthalmic and Vision Research",
  • each co-author is aware of the commercial relationships policy,
  • relevant commercial relationships are disclosed at the end of the abstract.

Submitted abstracts will be received by the congress secretariat. You will receive an e-mail notification confirming the reception of your abstract.

Peer review by the scientific committee will take about six weeks. Subsequently, you will be informed by e-mail about acceptance and type of presentation (poster or free paper).

You may withdraw your abstract by notifying the congress secretariat.

No exclusion with regard to the topics addressed is projected but studies without direct clinical relevance are preferred for submission to the Swiss Eye Research Meeting and have a high probability to get acceptance for posters only at the SOG-SSO meeting.

A first author may only present twice.


Deadlines

Abstracteinreichung
09.01.2023 Start Abstracteinreichung
12.04.2023 (Mitternacht) Verlängerung: Deadline Abstracteinreichung
Posterupload
01.06.2023 Start der Postereinreichung
26.07.2023 (Mitternacht) Deadline der Postereinreichung für die Teilnahme am Posterpreis
23.08.2023 (Mitternacht) Deadline der Postereinreichung
Klinische Monatsblätter
01.06.2023

Start der Einreichung
Login: https://mc.manuscriptcentral.com/klimo-sog
Richtlinien: Autorenrichtlinien

29.10.2023 (Mitternacht)

Extended Deadline der Einreichung


Kontakt

Falls Sie Fragen zur Abstracteinreichung haben, wenden Sie sich bitte an das Kongresssekretariat IMK: sascha.serno@imk.ch | abstracts@imk.ch